万珂在治疗多发性骨髓瘤中的临床应用

Clinical research of multiple myeloma with Velcade treatment

目的:观察蛋白酶体抑制剂硼替佐米(万珂)为主的化疗方案治疗多发性骨髓瘤(MM)的疗效和不良反应。方法:多发性骨髓瘤患者接受含有万珂的联合方案进行化疗。按照EBMT/ABMT标准进行疗效评定。结果:在接受万珂治疗的18例患者中,初治10例,复发难治8例;总有效率达83%,其中完全缓解(CR)3例,接近完全缓解(nCR)5例,部分缓解(PR)7例,死亡3例。主要不良反应包括周围神经病变、血小板减少、胃肠道反应以及病毒感染,经对症处理后好转,一般不影响治疗。结论:万珂对于初治和复发难治的多发性骨髓瘤是一种比较安全有效的治疗药物,起效较快,治疗反应率及完全缓解率较高。

Objective：To examine the efficacy and adverse reactions of proteasome inhibitor bortezomib（VELCADE）,a chemotherapy regimen in the treatment of multiple myeloma（MM）.Methods：The patients with multiple myeloma received a joint chemotherapy containing VELCADE.The efficacy was determined according to EBMT / ABMT criteria.Results：Out of 18 patients receiving the chemotherapy,10 patients were newly diagnosed and 8 cases were relapsed. The total effective rate was 83% consisting of 3 cases with complete response（CR）,5 patients with almost complete remission（nCR）,7 patients with partial remission（PR）,and 3 died.The main side effects include peripheral neuropathy,thrombocytopenia,gastrointestinal disorders and viral infections.These side effects were improved by symptomatic treatment and generally do not affect the treatment.Conclusion：For the newly diagnosed and relapsed or refractory multiple myeloma cases,VELCADE is a safe and effective therapeutic drugs with rapid onset,high treatment response rate and complete remission rate.